A detailed history of Capital International Investors transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Capital International Investors holds 3,129,010 shares of REGN stock, worth $3.29 Billion. This represents 0.62% of its overall portfolio holdings.

Number of Shares
3,129,010
Previous 2,915,972 7.31%
Holding current value
$3.29 Billion
Previous $2.56 Billion 17.59%
% of portfolio
0.62%
Previous 0.59%

Shares

23 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

BUY
$902.69 - $993.35 $192 Million - $212 Million
213,038 Added 7.31%
3,129,010 $3.01 Billion
Q4 2023

Feb 13, 2024

SELL
$775.18 - $881.7 $45.2 Million - $51.5 Million
-58,366 Reduced 1.96%
2,915,972 $2.56 Billion
Q3 2023

Nov 13, 2023

BUY
$692.45 - $844.37 $12.3 Million - $15 Million
17,723 Added 0.6%
2,974,338 $2.45 Billion
Q2 2023

Aug 11, 2023

BUY
$700.03 - $830.35 $562 Million - $667 Million
803,143 Added 37.3%
2,956,615 $2.12 Billion
Q1 2023

May 15, 2023

BUY
$680.49 - $826.97 $424 Million - $516 Million
623,529 Added 40.76%
2,153,472 $1.77 Billion
Q4 2022

Feb 14, 2023

SELL
$705.89 - $766.39 $167 Million - $182 Million
-237,193 Reduced 13.42%
1,529,943 $1.1 Billion
Q3 2022

Nov 14, 2022

SELL
$573.97 - $724.32 $14.2 Million - $18 Million
-24,799 Reduced 1.38%
1,767,136 $1.22 Billion
Q2 2022

Aug 15, 2022

BUY
$548.35 - $738.84 $59.2 Million - $79.8 Million
108,036 Added 6.42%
1,791,935 $1.06 Billion
Q1 2022

May 16, 2022

BUY
$595.12 - $698.43 $844 Million - $990 Million
1,417,899 Added 533.04%
1,683,899 $1.18 Billion
Q4 2021

Feb 14, 2022

SELL
$543.48 - $670.97 $471 Million - $581 Million
-865,968 Reduced 76.5%
266,000 $168 Million
Q3 2021

Nov 15, 2021

SELL
$574.03 - $680.96 $90.8 Million - $108 Million
-158,178 Reduced 12.26%
1,131,968 $685 Million
Q2 2021

Aug 16, 2021

SELL
$472.8 - $558.54 $7,092 - $8,378
-15 Reduced -0.0%
1,290,146 $721 Million
Q1 2021

May 14, 2021

SELL
$446.73 - $548.2 $33.4 Million - $40.9 Million
-74,665 Reduced 5.47%
1,290,161 $610 Million
Q4 2020

Feb 12, 2021

SELL
$478.3 - $607.98 $37.4 Million - $47.5 Million
-78,158 Reduced 5.42%
1,364,826 $659 Million
Q3 2020

Nov 13, 2020

SELL
$544.75 - $658.21 $69.5 Million - $83.9 Million
-127,490 Reduced 8.12%
1,442,984 $808 Million
Q2 2020

Aug 14, 2020

SELL
$493.32 - $643.92 $25.5 Million - $33.3 Million
-51,741 Reduced 3.19%
1,570,474 $979 Million
Q1 2020

May 15, 2020

BUY
$336.18 - $494.43 $35.2 Million - $51.8 Million
104,782 Added 6.91%
1,622,215 $792 Million
Q4 2019

Feb 18, 2020

BUY
$274.13 - $376.51 $137,887 - $189,384
503 Added 0.03%
1,517,433 $570 Million
Q3 2019

Nov 14, 2019

BUY
$273.46 - $318.39 $5,742 - $6,686
21 Added 0.0%
1,516,930 $421 Million
Q2 2019

Aug 14, 2019

SELL
$299.6 - $414.82 $18.6 Million - $25.8 Million
-62,205 Reduced 3.94%
1,516,909 $475 Million
Q1 2019

May 15, 2019

BUY
$372.08 - $439.57 $18.6 Million - $22 Million
50,002 Added 3.27%
1,579,114 $648 Million
Q4 2018

Feb 14, 2019

SELL
$335.82 - $403.04 $70.9 Million - $85 Million
-211,000 Reduced 12.13%
1,529,112 $571 Million
Q3 2018

Nov 14, 2018

BUY
$351.14 - $408.51 $611 Million - $711 Million
1,740,112 New
1,740,112 $703 Million

Others Institutions Holding REGN

About REGENERON PHARMACEUTICALS, INC.


  • Ticker REGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,190,000
  • Market Cap $113B
  • Description
  • Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...
More about REGN
Track This Portfolio

Track Capital International Investors Portfolio

Follow Capital International Investors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital International Investors, based on Form 13F filings with the SEC.

News

Stay updated on Capital International Investors with notifications on news.